Table 6.
Medication groups used for treating hypertensive T2D and non-T2D participants respectively
| ATC group | Use in treated participants with T2D | Use in treated participants without T2D | Comment | |||
|---|---|---|---|---|---|---|
| |
|
N = 760 (%) single or in combination with other preparations |
as spreparation/ATC group |
N = 3852 (%) single or in combination with other preparations |
as single preparation/ATC group |
|
|
C02 |
Anti-hypertensives |
9.47 |
2.11 |
8.00 |
2.78 |
|
|
C03 |
Diuretics |
29.47 |
2.50 |
17.29* |
2.52 |
not ideal as first line treatment since they can worsen glucose and lipid levels |
|
C04 |
Peripheral vasodilators |
4.21 |
0.13 |
2.65* |
0.31 |
|
|
C07 |
Beta blocking agents |
44.74 |
8.82 |
52.23* |
23.81* |
best used as second- or third-line treatments in T2D, more efficacious in younger patients (55–60 years), not for asthma patients, because of bronchoconstrictive effects, promote weight gain, may mask hypoglycaemia |
|
C08 |
Calcium channel blockers |
33.68 |
5.79 |
27.13* |
7.84* |
not recommended as first-line and single treatment |
| C09 | Agents acting on the renin-angiotensin system | 68.95 | 20.53 | 51.43* | 18.98 | recommended as first-line treatment, reduce the risk for renal end points |
* p for the difference between participants with T2D and participants without T2D <0.05.
Anti-hypertensive medication in participants who were classified as non-hypertensive or unknown was not considered in this analysis, assuming that they used these agents for different indications.